- Home
- EYPT vs NMG Comparison
EYPT vs NMG Comparison
Compare EYPT & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | NMG |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Other Metals and Minerals |
| Sector | Industrials | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.9M | 414.7M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EYPT | NMG |
|---|---|---|
| Price | $4.62 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $31.80 | $5.75 |
| AVG Volume (30 Days) | ★ 6.3M | 358.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,115.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $1.26 |
| 52 Week High | $19.11 | $6.06 |
Technical Indicators
Market Signals| Indicator | EYPT | NMG |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 45.27 |
| Support Level | $3.95 | $1.38 |
| Resistance Level | $15.17 | $1.67 |
| Average True Range (ATR) | 0.51 | 0.06 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 26.30 | 12.50 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.